- American City Business Journals•14 hours ago
The Food and Drug Administration granted marketing approval Wednesday to Vantrela ER, an extended release pain medicine developed by Teva Pharmaceutical Industries that is formulated using the company’s proprietary abuse deterrence technology. Vantrela ER was approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Company officials said the product’s abuse-deterrent properties that are expected to reduce, but not totally prevent, oral, intranasal and intravenous abuse of the drug when the tablets are manipulated.
- Business Wire•17 hours agoTeva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets Formulated with Proprietary Abuse Deterrence Technology
Teva Pharmaceutical Industries Ltd. today announced the U.S. Food and Drug Administration approved VANTRELATM ER extended-release tablets formulated with Teva’s proprietary abuse deterrence technology.
History has taught us that dividend growth stocks are the absolute best way to grow both your income and wealth over time. One such group of dividend stocks is known as the S&P 500 Dividend Aristocrats -- S&P 500 companies that have increased their payouts for at least 25 consecutive years. Of course, to be able to pay secure and growing dividends, a company needs to have a strong competitive advantage that gives it good pricing power and allows it to generate strong free cash flow.
TEVA.TA : Summary for TEVA PHARMA IND ILS0.1 - Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA.TA)
Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Add to watchlist
|Bid||12,840.00 x 200|
|Ask||12,850.00 x 34100|
|Day's Range||12,840.00 - 12,960.00|
|52 Week Range||128.40 - 12,960.00|
|PE Ratio (TTM)||7,469.46|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|